Atara Biotherapeutics Inc (ATRA NASDAQ) stock market data APIs
$7.5404
-0.61(-8.1%)
as of April 24, 2025
Atara Biotherapeutics Inc Financial Data Overview
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Prev. Close
7.5404
Open
6.9302
High
7.8196
Low
7.0028
52 wk Range
5.005-19
Market Cap
44 528 K
Shares Outstanding
5 859 K
Revenue
129 M
EPS
-1.19
Beta
0.323
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Atara Biotherapeutics Inc data using free add-ons & libraries
Get Atara Biotherapeutics Inc Fundamental Data
Atara Biotherapeutics Inc Fundamental data includes:
- Net Revenue: 129 M
- EBITDA: -73 280 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-26
- EPS/Forecast: -3.4875
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Atara Biotherapeutics Inc News
New
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder r...
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder r...
Seth Klarman's Exit from Atara Biotherapeutics Inc
Overview of Seth Klarman (Trades, Portfolio)'s Recent Stock Transaction Warning! GuruFocus has detected 7 Warning Signs with ATRA. Renowned value investor Seth Klarman (Trades, Portfolio), through T...
Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding
Overview of Seth Klarman (Trades, Portfolio)'s Recent Stock Transaction Warning! GuruFocus has detected 7 Warning Signs with ATRA. Renowned value investor Seth Klarman (Trades, Portfolio), through T...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
